Why BioAge Labs, Inc.’s (BIOA) Stock Is Down 5.19%
As of Tuesday, September 15, BioAge Labs, Inc.’s BIOA share price has dipped by 5.19%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Commentary & Analysis
Why BioAge Labs, Inc.’s (BIOA) Stock Is Down 5.13%
As of Thursday, September 10, BioAge Labs, Inc.’s BIOA share price has dipped by 5.13%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why BioAge Labs, Inc.’s (BIOA) Stock Is Up 5.54%
As of Tuesday, August 25, BioAge Labs, Inc.’s BIOA share price has surged by 5.54%, which has investors questioning if this is right time to sell.Michael Rose
Why BioAge Labs, Inc.’s (BIOA) Stock Is Up 10.94%
As of Friday, August 21, BioAge Labs, Inc.’s BIOA share price has surged by 10.94%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Is BioAge Labs, Inc. (BIOA) Overvalued?
We dive into why BioAge Labs, Inc. (BIOA) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Tudor Pop
Financial Summary
| Share Statistics | BIOA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $369.9 | $586.4 | 34% |
|
| Shares Out (Mil) | 44.8 | 43.1 | 45% |
|
| Institutional Ownership | 97.0% | 83.7% | 72% |
|
| Float (Mil) | 39.2 | 45.1 | 42% |
|
| Beta | na | 0.73 | na |
|
| Avg Daily Volume (000s) | 673 | 331 | 62% |
|
| Price Change (52-week) |
61.2% | 63.2% | 86% |
|
| Growth | BIOA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.608) | ($2.374) | ($2.414) | |
| Month Ago EPS | ($0.608) | ($2.374) | ($2.360) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.656) | ($2.492) | ($2.060) | |
| Year/Year Chg | 4.5% | 5.8% | 20.9% | |
| Financials | BIOA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $10 | $317 | 9% |
|
| Net Income (TTM) (Mil) | ($95) | ($11) | 11% |
|
| EPS (TTM) | ($2.371) | ($0.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($88) | ($6) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($146) | $5 | 12% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $6 | 20% |
|
| Enterprise Value (Q1) (Mil) | $57 | $515 | 17% |
|
| Valuation | BIOA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.98 | 2.51 | 22% |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BIOA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (747.8%) | 69.4% | 0% |
|
| Net Margin | (912.3%) | 2.5% | 0% |
|
| ROA | (26.3%) | (22.4%) | 18% |
|
| ROE | (28.2%) | (21.8%) | 20% |
|
| Liabilities to Assets | 5.5% | 32.4% | 3% |
|
| F-Score | 4 | 3 | 33% |
|
BioAge Labs, Inc. did not pass any screens on 9/18/2026.
